News – Page 1052 – Endpoints News

Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

8 years ago

Done deal? Takeda reaches a ‘breakthrough’ in Shire merger talks as deal announcement looms — Reuters

8 years ago

Arrested and charged with fraud, PixarBio CEO Frank Reynolds could face up to 20 years in prison

8 years ago

SCOTUS to biopharma: Inter partes reviews are here to stay, deal with it

8 years ago

Sofinnova leads $32.4 million round for Italy's EryDel; Celgene expands collaboration with Zymeworks

8 years ago

Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron's share price swooned

8 years ago

Shire says Takeda has come up with a new buyout offer as reports spotlight a looming handshake deal

8 years ago

Protein degradation 2.0? Third Rock sinks $56M into Cedilla's unusual approach

8 years ago

Nextech leads a $56M round for the Revolution's move into the clinic

8 years ago

AstraZeneca’s Imfinzi/tremelimumab combo fizzles again on lung cancer

8 years ago

Longtime Sanofi R&D chief Elias Zerhouni is on his way out, handing the research reins to Roche vet John Reed

8 years ago

FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case

8 years ago

FDA panel offers a wavering thumbs up for Eli Lilly's 2 mg baricitinib, thumbs down on 4 mg

8 years ago

Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion

8 years ago

The under-40s: How does the next generation of biopharma executives view the future?

8 years ago

Sanofi loses its German CSO and diabetes chief to Grünenthal; Roche touts longterm advantages of Ocrevus in treating ...

8 years ago

EMA committee recommends Alnylam's early-stage ATTR amyloidosis drug for orphan status

8 years ago

Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine

8 years ago

Sage files for an approval for its ‘breakthrough’ therapy for postpartum depression

8 years ago

Penny stock biotech Synthetic Biologics sees its 'breakthrough' status pulled as FDA ponders safety issues

8 years ago

Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage

8 years ago

Dicerna shares rocket up on a $15M-plus-stock deal to settle Alnylam claims — will deals follow?

8 years ago

After fruitless talks, a bid from Vas and plenty of patience, AveXis CEO Sean Nolan slowly reeled in an $8.7B deal

8 years ago

Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire

8 years ago

First page Previous page 1049 1050 105110521053 1054 1055 Next page Last page